Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Melanoma 12Sarcoma 3Neoplasm Metastasis 3Triple Negative Breast Neoplasms 2Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Rectal Neoplasms 1Pleural Effusion, Malignant 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Lung Neoplasms 1Inflammatory Breast Neoplasms 1Hemangiosarcoma 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Merkel Cell 1Carcinoma, Hepatocellular 1Carcinoma, Ductal, Breast 1Carcinoma, Ductal 1Advanced Non CNS Tumors 1Adenocarcinoma 1

Interventions

talimogene laherparepvec 1Surgical Procedures, Operative 1Sentinel Lymph Node Biopsy 1Pemetrexed 1Paclitaxel 1Mastectomy, Subcutaneous 1Mammaplasty 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Ductal × talimogene laherparepvec × Clear all
NCT02779855 2026-03-10

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Completed
50 enrolled 12 charts
Breast

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Ductal, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡